enVVeno Medical (NASDAQ:NVNO) Shares Scheduled to Reverse Split on Tuesday, January 20th

enVVeno Medical Corporation (NASDAQ:NVNO) shares are set to reverse split before the market opens on Tuesday, January 20th. The 1-35 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, January 19th.

enVVeno Medical Stock Down 13.2%

NASDAQ:NVNO opened at $0.31 on Friday. enVVeno Medical has a twelve month low of $0.30 and a twelve month high of $5.62. The firm has a market capitalization of $6.34 million, a price-to-earnings ratio of -0.29 and a beta of 1.04. The stock’s 50 day moving average price is $0.38 and its two-hundred day moving average price is $1.64.

enVVeno Medical (NASDAQ:NVNO) last issued its earnings results on Thursday, October 30th. The company reported ($0.23) earnings per share for the quarter. As a group, analysts anticipate that enVVeno Medical will post -1.32 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of enVVeno Medical in a report on Monday, December 29th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Reduce”.

Institutional Trading of enVVeno Medical

Several large investors have recently bought and sold shares of NVNO. Jane Street Group LLC acquired a new position in enVVeno Medical during the second quarter worth about $51,000. Creative Planning acquired a new position in enVVeno Medical during the 2nd quarter worth approximately $54,000. CM Management LLC acquired a new position in enVVeno Medical during the 3rd quarter worth approximately $544,000. Geode Capital Management LLC lifted its stake in enVVeno Medical by 1.1% in the 2nd quarter. Geode Capital Management LLC now owns 199,509 shares of the company’s stock valued at $796,000 after purchasing an additional 2,211 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in enVVeno Medical in the second quarter valued at approximately $798,000. 34.71% of the stock is owned by institutional investors and hedge funds.

About enVVeno Medical

enVVeno Medical, Inc is a clinical‐stage medical device company focused on the development and commercialization of subcutaneous vascular access systems for patients requiring repeated or long‐term intravenous therapy. Through its proprietary Freedom® platform, the company aims to offer an implantable alternative to traditional peripherally inserted central catheters (PICCs) and external tunneled catheters, addressing complications such as infection risk, dislodgement and patient discomfort.

The company’s lead product candidate, the Freedom PICC System, consists of a low‐profile, subcutaneous port connected to a flexible catheter designed for peripheral insertion.